[go: up one dir, main page]

WO2025211624A1 - Composition contenant le composé k permettant d'améliorer ou d'augmenter l'éclat ou la transparence de la peau - Google Patents

Composition contenant le composé k permettant d'améliorer ou d'augmenter l'éclat ou la transparence de la peau

Info

Publication number
WO2025211624A1
WO2025211624A1 PCT/KR2025/003731 KR2025003731W WO2025211624A1 WO 2025211624 A1 WO2025211624 A1 WO 2025211624A1 KR 2025003731 W KR2025003731 W KR 2025003731W WO 2025211624 A1 WO2025211624 A1 WO 2025211624A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
skin
compound
expression
transparency
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/KR2025/003731
Other languages
English (en)
Korean (ko)
Inventor
김아영
정지용
조시영
김동현
홍용덕
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amorepacific Corp
Original Assignee
Amorepacific Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amorepacific Corp filed Critical Amorepacific Corp
Publication of WO2025211624A1 publication Critical patent/WO2025211624A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/92—Oral administration

Definitions

  • the present disclosure relates to a composition containing compound K for improving or increasing skin radiance or clarity.
  • Figure 1 shows the results of a skin cytotoxicity test of compound K.
  • Figures 2a to 2c show the results of confirming changes in the expression of KRT10, KLF4, and MMP-1 in an environment of accelerated skin aging caused by UVB treatment.
  • Figures 4a to 4c show the results of confirming changes in the expression of KRT10, KLF4, and MMP-1 in an environment of accelerated skin aging caused by blue light (HEV) treatment.
  • HEV blue light
  • Figures 5a to 5c show the results of confirming the efficacy of compound K on KRT10, KLF4, and MMP-1 in a skin accelerated aging environment caused by UVB treatment.
  • Figures 6a to 6c show the results of confirming the efficacy of compound K on KRT10, KLF4, and MMP-1 in an environment of accelerated skin aging caused by fine dust (PM2.5) treatment.
  • Figures 7a to 7c show the results of confirming the efficacy of compound K on KRT10, KLF4, and MMP-1 in a skin accelerated aging environment caused by blue light (HEV) treatment.
  • HEV blue light
  • Figures 8a and 8b show the results of confirming the efficacy of compound K in restoring KRT10 (K10) and KLF4 expression on artificial skin subjected to accelerated aging by ultraviolet treatment.
  • Figures 9a and 9b show the results of confirming the efficacy of compound K in improving skin radiance or transparency on artificial skin subjected to accelerated aging by ultraviolet treatment.
  • the present invention may relate to a composition for improving or increasing skin radiance or transparency, comprising compound K.
  • the present invention may relate to the use of compound K for preparing a composition for improving or increasing skin radiance or clarity.
  • the present invention may relate to non-therapeutic uses of compound K for improving or increasing skin radiance or clarity.
  • skin radiance and transparency are determined by the reflection of light when it strikes the skin.
  • the light that is reflected directly determines the skin's radiance, while the light transmitted through the skin determines its transparency.
  • Skin with high transparency is skin that reflects a large amount of light from within the skin when light of the same intensity is incident on the skin, and can be said to have a large diffuse reflection.
  • Skin radiance is greatly affected by the nature and condition of the skin surface, and causes of reduced skin transparency include a decrease in gloss due to diffuse reflection on the skin surface.
  • the compound K may be contained in an amount of 0.0002 to 0.04 wt% relative to the total weight of the composition. Specifically, the compound K may be included in an amount of 0.0002 wt% or more, 0.0003 wt% or more, 0.0004 wt% or more, 0.0005 wt% or more, 0.0006 wt% or more, 0.0007 wt% or more, 0.0008 wt% or more, 0.0009 wt% or more, 0.001 wt% or more, 0.002 wt% or more, 0.003 wt% or more, 0.004 wt% or more, 0.005 wt% or more, 0.006 wt% or more, 0.007 wt% or more, 0.008 wt% or more, 0.009 wt% or more, 0.01 wt% or more, or 0.02 wt% or more, relative to the total weight of the composition, and further, the compound K may be included in an amount of
  • the compound K can improve barrier function in the epidermal layer by increasing the expression of KRT10.
  • the compound K can increase the expression of KLF4.
  • KLF4 is a biomarker associated with stem cell potential in the epidermal layer, and a decrease in the expression of KLF4 indicates a decrease in stem cell potential in the epidermal layer.
  • the compound K can inhibit the expression of MMP-1.
  • MMP-1 is an enzyme that decomposes collagen present in the dermis, and an increase in the expression of MMP-1 indicates that the dermis has collapsed and elasticity has decreased.
  • the compound K can effectively improve or increase skin radiance or transparency by acting on both the epidermal layer and the dermal layer by increasing the expression of at least one of KRT10 and KLF4 and inhibiting the expression of MMP-1, thereby making the skin layer uniform and smooth.
  • the composition may be a cosmetic composition.
  • the above cosmetic composition is not particularly limited in its formulation and may be appropriately selected depending on the intended purpose.
  • it may be manufactured in the form of a skin lotion, skin softener, skin toner, lotion, milk lotion, moisture lotion, nutrition lotion, massage cream, nutrition cream, moisture cream, hand cream, foundation, essence, nutrition essence, pack, soap, cleansing foam, cleansing lotion, cleansing cream, cleansing water, powder, body lotion, body cream, body oil, body cleanser, and body essence.
  • the formulation of the above cosmetic composition is a paste, cream or gel, animal fiber, plant fiber, wax, paraffin, starch, tragacanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide may be used as a carrier component.
  • lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component, and particularly in the case of a spray, a propellant such as chlorofluorohydrocarbon, propane/butane or dimethyl ether may be additionally included.
  • a solvent, solvating agent or emulsifying agent is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylglycol oil, glycerol aliphatic ester, polyethylene glycol or fatty acid ester of sorbitan.
  • the formulation of the above cosmetic composition is a surfactant-containing cleansing
  • aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyl taurate, sarcosinate, fatty acid amide ether sulfate, alkylamidobetaine, fatty alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, linolenic derivative, or ethoxylated glycerol fatty acid ester may be used as a carrier component.
  • the determination of the dosage or intake amount of the active ingredient is within the level of a person skilled in the art, and may vary depending on various factors such as the age, health condition, and complications of the subject to be administered or consumed.
  • the non-therapeutic oral composition or food composition according to one embodiment of the present invention may include various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic flavoring agents and natural flavoring agents, coloring agents and enhancers (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, etc.
  • the non-therapeutic oral composition or food composition according to one embodiment of the present invention may include fruit pulp for the production of natural fruit juice and fruit juice drinks and vegetable drinks. These components may be used independently or in combination. The proportion of these additives is not so critical, but is typically included in the range of 0 to about 60 parts by weight per 100 parts by weight of the composition according to one embodiment of the present invention.
  • the present invention may provide, as an example, the following embodiments.
  • the first embodiment can provide a composition for improving or increasing skin radiance or transparency, containing compound K.
  • a third embodiment can provide a composition according to at least one of the first embodiment and the second embodiment, wherein the compound K increases the expression of KRT10.
  • a fourth embodiment can provide a composition according to one or more of the first to third embodiments, wherein the compound K increases the expression of KLF4.
  • a sixth embodiment can provide a composition according to one or more of the first to fifth embodiments, wherein the compound K improves a barrier function in the epidermal layer.
  • the ninth embodiment can provide a composition that is a cosmetic composition according to one or more of the first to eighth embodiments.
  • human epidermal keratinocytes were seeded at 1x104 in a 96-well plate and cultured for 24 hours. The cells were then treated with Compound K at final concentrations of 0.5 ppm, 1 ppm, 2 ppm, and 4 ppm per well, respectively, and cultured for 24 hours. 10 ⁇ l of Cell Counting Kit-8 (CCK-8) solution was added to each well and cultured at 37°C for 2 hours. The absorbance was measured at 450 nm, and the cell proliferation and toxicity effects were calculated as a percentage based on the absorbance of the control group. The results are shown in Fig. 1.
  • Epidermolytic hyperkeratosis is a genetic disorder caused by mutations in KRT10, which results in the inability to express it. This condition causes thick, dark, scaly skin and makes it brittle. Specifically, KRT10 plays a crucial role in skin barrier function through keratin formation, smoothing the skin surface. Therefore, restoring KRT10 expression, which decreases with age, smooths the skin surface and increases radiance and clarity.
  • Keratinocyte stem cells are responsible for the self-division of keratinocytes. They ensure the continued production of keratinocytes and play a crucial role in determining the formation and shedding of keratin. As we age, the stem cell capacity of keratinocytes declines, leading to phenomena such as increased keratin size and decreased shedding rates, which in turn affect the roughness of the skin surface. Therefore, restoring the expression of KLF4, a gene responsible for stem cell capacity, normalizes stem cell capacity and keratin formation, thereby increasing the uniformity of the skin surface.
  • MMP-1 is an enzyme that breaks down collagen proteins. Collagen proteins are present in the dermis, and their degradation damages the dermal ECM structure, causing wrinkles. Therefore, suppressing MMP-1 expression inhibits collagen protein degradation, strengthening the dermal structure and preventing the loss of skin clarity that can occur due to decreased skin elasticity.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Cosmetics (AREA)

Abstract

La présente divulgation concerne une composition permettant d'améliorer ou d'augmenter l'éclat ou la transparence de la peau, contenant le composé K. Plus particulièrement, la composition permettant d'améliorer ou d'augmenter l'éclat ou la transparence de la peau, selon la présente divulgation, améliore la fonction barrière par augmentation de l'expression de KRT10 dans la couche épidermique et, en même temps, maintient le caractère souche par récupération de l'expression de KLF4, et supprime la dégradation du collagène par inhibition de l'expression de MMP-1 dans la couche dermique, et ainsi, en agissant à la fois sur la couche épidermique et la couche dermique, peut réduire efficacement la détérioration de l'éclat ou de la transparence de la peau qui est provoquée par des couches cutanées irrégulières dues au vieillissement.
PCT/KR2025/003731 2024-04-04 2025-03-24 Composition contenant le composé k permettant d'améliorer ou d'augmenter l'éclat ou la transparence de la peau Pending WO2025211624A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2024-0045897 2024-04-04
KR1020240045897A KR20250147434A (ko) 2024-04-04 2024-04-04 컴파운드 k를 함유하는 피부 광채 또는 투명도 개선 또는 증가용 조성물

Publications (1)

Publication Number Publication Date
WO2025211624A1 true WO2025211624A1 (fr) 2025-10-09

Family

ID=97267712

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2025/003731 Pending WO2025211624A1 (fr) 2024-04-04 2025-03-24 Composition contenant le composé k permettant d'améliorer ou d'augmenter l'éclat ou la transparence de la peau

Country Status (2)

Country Link
KR (1) KR20250147434A (fr)
WO (1) WO2025211624A1 (fr)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101928797B1 (ko) 2012-06-29 2018-12-17 (주)아모레퍼시픽 컴파운드 ｋ를 함유하는 피부 외용제 조성물

Also Published As

Publication number Publication date
KR20250147434A (ko) 2025-10-13

Similar Documents

Publication Publication Date Title
WO2013027984A2 (fr) Composition cosmétique contenant un composant de thé vert
KR101972071B1 (ko) 피부톤 개선 또는 피부 탄력 증진용 화장료 조성물
WO2017164517A1 (fr) Composition antivieillissement contenant des vésicules de type exosome dérivées de ginseng en tant que principe actif
WO2012067404A2 (fr) Composition anti-vieillissement contenant artemisia annua l. comme principe actif
JP2003201229A (ja) マトリックスメタロプロテアーゼ活性阻害剤および抗老化用化粧料
WO2010143879A2 (fr) Composition cosmétique destinée à éliminer les rides, contenant un extrait d'ormeau en tant que principe actif
KR20170031386A (ko) 유칼립투스 잎과 붉은토끼풀 잎의 혼합 추출물을 함유하는 화장료 조성물
JP2004067590A (ja) 女性ホルモン産生促進剤及びこれを含有する皮膚外用剤
WO2019143055A1 (fr) Composition comprenant un extrait de haricots fermentés obtenu à partir d'une fermentation par une souche d'aspergillus fumigatus, pour l'amélioration de soins cutanés
WO2019107831A2 (fr) Composition pour prévenir ou améliorer le vieillissement intrinsèque comprenant de la paéoniflorine ou de l'albiflorine
KR102144568B1 (ko) 상백피 추출물을 유효성분으로 포함하는 피부외용제 조성물
CN107635561B (zh) 含有茶皂醇衍生物作为活性成分的组合物
WO2007081190A1 (fr) Nouvelle utilisation de 1,2,3,4,6-penta-o-galloyl-beta-d-glucose
WO2022158809A1 (fr) Composition pour promouvoir la croissance capillaire et prévenir l'alopécie, comprenant de l'acide atrarique
JPH1029924A (ja) 抗老化剤
WO2025211624A1 (fr) Composition contenant le composé k permettant d'améliorer ou d'augmenter l'éclat ou la transparence de la peau
JP2011225550A (ja) マトリックスメタロプロテアーゼ産生抑制及びエラスターゼ活性阻害剤
WO2020101414A1 (fr) Composition favorisant la régénération cutanée et la poussée capillaire, contenant de l'apigénine
WO2025211626A1 (fr) Composition contenant du composé k pour améliorer le cycle de renouvellement de la peau
WO2025211625A1 (fr) Composition contenant du composé k pour réduire le relâchement cutané
WO2022139458A1 (fr) Composition de soins de la peau
KR102145023B1 (ko) 미역추출물 및 콜라겐 펩타이드를 포함하는 조성물
WO2022050819A1 (fr) Composition anti-inflammatoire pour réduire les rides cutanées et hydrater et activer la régénération de la peau, contenant, en tant que principe actif, un extrait d'huile de krill traitée par une enzyme
KR101273027B1 (ko) 캄페롤을 유효성분으로 함유하는 피지 분비 억제용 및항비만용 조성물
WO2015030422A1 (fr) Composition pour accélérer la restauration des cheveux ou la croissance des cheveux, comprenant du 21-o-angéloylthéasapogénol e3

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 25782827

Country of ref document: EP

Kind code of ref document: A1